Проведено исследование, посвященное терапии акушерского антифосфолипидного синдрома у женщин с привычным выкидышем, путем назначения низкомолекулярного гепарина – бемипарина. Получены результаты, свидетельствующие о терапевтическом воздействии препарата в профилактических и терапевтических дозах, побочных эффектов не зарегистрировано. Удалось достичь пролонгирования беременности до доношенного срока в 93,5% наблюдений, преждевременные роды в связи с плацентарной недостаточностью отмечены в 6,5% случаев. Ни в одном наблюдении не отмечено тромбозов, тромбоцитопении, кровотечений во II и III триместрах беременности. При родоразрешениях кровопотеря не превышала нормативных показателей. Антикоагулянтная терапия бемипарином была продолжена в течение 6 нед послеродового периода для профилактики тромботических осложнений. Ключевые слова: антифосфолипидный синдром, привычный выкидыш, преждевременные роды, венозная тромбоэмболия, низкомолекулярные гепарины, бемипарин, плацентарная недостаточность.
________________________________________________
A study on the treatment of obstetric antiphospholipid syndrome in women with recurrent miscarriage by assigning low molecular weight heparin – bemiparin. The results show that the therapeutic effects of the drug as a preventive and therapeutic doses side effects are not registered. It was possible to achieve a full-term pregnancy to prolong life in 93.5% of cases, premature birth due to placental insufficiency observed in 6.5% of cases. None of the observation is marked by thrombocytopenia, bleeding in the second and third trimesters of pregnancy. At delivery blood loss did not exceed the standard indicators. Anticoagulation bemiparin based therapy was continued for 6 weeks of the postpartum period for the prevention of thrombotic complications. Key words: antiphospholipid syndrome, habitual miscarriage, premature birth, low molecular weight heparin, bemiparin, placental.
1. Abbasi N, Balayla J, Laporta DP et al. Trends, risk factors and mortality among women with venous thromboembolism during labour and delivery: a population-based study of 8 million births. Arch Gynecol Obstet.
2. Palareti G. Pregnancy and venous thrombosis [haematologica reports] 2005; 1 (10): 13–7.
3. Stein PD, Hull RD, Kayali F et al. Venous thromboembolism in pregnancy: 21-year trends. Am J Med 2004; 117: 121–5.
4. Тетруашвили Н.К. Клинико-анамнестический анализ и структура причин привычных ранних потерь беременности. Врач. 2008; 7. / Tetruashvili N.K. Kliniko-anamnesticheskii analiz i struktura prichin privychnykh rannikh poter' beremennosti. Vrach. 2008; 7. [in Russian]
5. Cervera R, Font J, Gomez Puerta JA et al. Catastrophic Antiphospholipid Syndrome Registry Project Group. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 2005; 64: 1205–9.
6. Серов В.Н., Сидельникова В.М., Агаджанова А.А., Тетруашвили Н.К. Плацентарная недостаточность в клинике невынашивания беременности. Рус. мед. журн. 2003; 11 (16): 938–40. / Serov V.N., Sidel'nikova V.M., Agadzhanova A.A., Tetruashvili N.K. Platsentarnaia nedostatochnost' v klinike nevynashivaniia beremennosti. Rus. med. zhurn. 2003; 11 (16): 938–40. [in Russian]
7. Антифосфолипидный синдром в акушерской практике. Под ред. А.Д.Макацария. М.: Руссо, 2000. / Antifosfolipidnyi sindrom v akusherskoi praktike. Pod red. A.D.Makatsariia. M.: Russo, 2000. [in Russian]
8. Макацария А.Д., Бицадзе В.О. Тромбофилии и противотромботическая терапия в акушерской практике. М.: Триада-Х, 2003. / Makatsariia A.D., Bitsadze V.O. Trombofilii i protivotromboticheskaia terapiia v akusherskoi. M.: Triada-Kh, 2003. [in Russian]
9. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология. 2010; 4 (1): 42. / Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniiu i profilaktike venoznykh tromboembolicheskikh oslozhnenii. Flebologiia. 2010; 4 (1): 42. [in Russian]
10. Bick RL, Frenkel EP, Backer WF, Sarode R. Hematological complications in obstetrics, pregnancy, and gynecology. UK, Cambridge University press, 2006; p. 604.
11. Lumpkin MM. FDA public health advisory. Anesthesiology 1998; 88: 27A–28A.
12. Navarro-Quilis A et al. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial; J Thromb Haemost 2003; 1 (3): 425–32.
13. Pettker C, Lockwood C. Pregnancy and venous thrombosis. The Global Library of Women’s Medicine.
14. Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004; 114 (5–6): 409–14.
15. Brill-Edwards P, Ginsberg JS, Gent M et al. Recurrence of Clot in This Pregnancy Study Group Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000; 343 (20): 1439–44.
16. Шулутко Е.М. Бемипарин – низкомолекулярный гепарин второго поколения в лечении и профилактике венозных тромбоэмболий. Трудный пациент. 2007; 15–16: 5–10. / Shulutko E.M. Bemiparin – nizkomolekuliarnyi geparin vtorogo pokoleniia v lechenii i profilaktike venoznykh tromboembolii. Trudnyi patsient. 2007; 15–16: 5–10. [in Russian]
17. Gómez-Outes A, Rocha E, Martínez-González J, Kakkar VV. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis. Pharmacoeconomics 2006; 24: 81–92.
________________________________________________
1. Abbasi N, Balayla J, Laporta DP et al. Trends, risk factors and mortality among women with venous thromboembolism during labour and delivery: a population-based study of 8 million births. Arch Gynecol Obstet.
2. Palareti G. Pregnancy and venous thrombosis [haematologica reports] 2005; 1 (10): 13–7.
3. Stein PD, Hull RD, Kayali F et al. Venous thromboembolism in pregnancy: 21-year trends. Am J Med 2004; 117: 121–5.
4. Tetruashvili N.K. Kliniko-anamnesticheskii analiz i struktura prichin privychnykh rannikh poter' beremennosti. Vrach. 2008; 7. [in Russian]
5. Cervera R, Font J, Gomez Puerta JA et al. Catastrophic Antiphospholipid Syndrome Registry Project Group. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 2005; 64: 1205–9.
6. Serov V.N., Sidel'nikova V.M., Agadzhanova A.A., Tetruashvili N.K. Platsentarnaia nedostatochnost' v klinike nevynashivaniia beremennosti. Rus. med. zhurn. 2003; 11 (16): 938–40. [in Russian]
7. Antifosfolipidnyi sindrom v akusherskoi praktike. Pod red. A.D.Makatsariia. M.: Russo, 2000. [in Russian]
8. Makatsariia A.D., Bitsadze V.O. Trombofilii i protivotromboticheskaia terapiia v akusherskoi. M.: Triada-Kh, 2003. [in Russian]
9. Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniiu i profilaktike venoznykh tromboembolicheskikh oslozhnenii. Flebologiia. 2010; 4 (1): 42. [in Russian]
10. Bick RL, Frenkel EP, Backer WF, Sarode R. Hematological complications in obstetrics, pregnancy, and gynecology. UK, Cambridge University press, 2006; p. 604.
11. Lumpkin MM. FDA public health advisory. Anesthesiology 1998; 88: 27A–28A.
12. Navarro-Quilis A et al. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial; J Thromb Haemost 2003; 1 (3): 425–32.
13. Pettker C, Lockwood C. Pregnancy and venous thrombosis. The Global Library of Women’s Medicine.
14. Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004; 114 (5–6): 409–14.
15. Brill-Edwards P, Ginsberg JS, Gent M et al. Recurrence of Clot in This Pregnancy Study Group Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000; 343 (20): 1439–44.
16. Shulutko E.M. Bemiparin – nizkomolekuliarnyi geparin vtorogo pokoleniia v lechenii i profilaktike venoznykh tromboembolii. Trudnyi patsient. 2007; 15–16: 5–10. [in Russian]
17. Gómez-Outes A, Rocha E, Martínez-González J, Kakkar VV. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis. Pharmacoeconomics 2006; 24: 81–92.
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России. 117997, Россия, Москва, ул. Академика Опарина, д. 4
*tetrauly@mail.ru
V.I.Kulakov Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation.
1179974, Russian Federation, Moscow, ul. Akademika Oparina, d. 4
*insufficiencytetrauly@mail.ru